Aslan Pharmaceuticals (ASLN) has released an update.
Aslan Pharmaceuticals has initiated voluntary liquidation for its main operating subsidiary after a strategic review, leading to the termination of all employees. The company, facing delisting from the Nasdaq due to non-compliance with listing requirements, has appointed Quantuma (Singapore) as the liquidator to explore strategic alternatives for its key assets, eblasakimab and farudodstat, while also preparing to liquidate under Cayman law.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.
